Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8300754 | 0.86 | L3MBTL1 (0.52) | L3MBTL1NPSR1HDAC3HDAC1HDAC2 | |
| SCHEMBL5862801 | 0.85 | L3MBTL1 (0.49) | L3MBTL1NPSR1HDAC3HDAC1HDAC2 | |
| SCHEMBL3145649 | 0.84 | L3MBTL1 (0.46) | L3MBTL1NPSR1SYKPPARA | |
| SCHEMBL3209123 | 0.83 | ALDH1A1 (0.43) | L3MBTL1 | |
| SCHEMBL1913579 | 0.83 | L3MBTL1 (0.49) | L3MBTL1NPSR1HDAC3HDAC1HDAC2 | |
| SCHEMBL1913578 | 0.83 | L3MBTL1 (0.49) | L3MBTL1NPSR1HDAC3HDAC1HDAC2 | |
| SCHEMBL7616466 | 0.82 | L3MBTL1 (0.51) | L3MBTL1NPSR1HDAC3HDAC1HDAC2 | |
| SCHEMBL15320116 | 0.82 | NPSR1 (0.52) | L3MBTL1NPSR1HDAC3HDAC1HDAC2 | |
| SCHEMBL15318909 | 0.82 | NPSR1 (0.52) | L3MBTL1NPSR1HDAC3HDAC1HDAC2 | |
| SCHEMBL8362357 | 0.81 | L3MBTL1 (0.47) | L3MBTL1NPSR1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754886-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | US | disclosed |
| EP-1318978-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2006-02-08 | — | — | EP | disclosed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | L3MBTL1 189/4885NPSR1 2840/4885HDAC3 436/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | L3MBTL1 107/4885NPSR1 3282/4885HDAC3 276/4885 |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BCOR | L3MBTL1 138/4885NPSR1 3274/4885HDAC3 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.